Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomized Double-Blind Study of IV Eravacycline vs Ertapenem in Complicated Urinary Tract Infections
2016-002207-26Phase 3Completed
- Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eravacycline in complicated urinary tract infection (cUTI) (2 arms), sponsored by Tetraphase Pharmaceuticals, Inc. Primary endpoints: Primary microbiologic outcome at test-of-cure (micro-MITT population) and Primary microbiologic outcome at test-of-cure (ME population). Started Oct 2016; status: completed.
02
Drugs
eravacycline
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2016-002207-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002207-26.